Inventiva (NASDAQ:IVA) Shares Gap Up Following Analyst Upgrade

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price gapped up prior to trading on Tuesday after Leerink Partnrs upgraded the stock to a strong-buy rating. The stock had previously closed at $5.45, but opened at $5.71. Inventiva shares last traded at $5.6260, with a volume of 120,111 shares.

A number of other equities analysts have also recently issued reports on the stock. Guggenheim decreased their price objective on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. UBS Group began coverage on Inventiva in a research note on Wednesday, January 7th. They issued a “buy” rating and a $12.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Wednesday, October 8th. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 price objective on shares of Inventiva in a research report on Tuesday, September 30th. Finally, Wall Street Zen raised Inventiva to a “hold” rating in a research note on Saturday, October 18th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $16.00.

Hedge Funds Weigh In On Inventiva

Institutional investors and hedge funds have recently modified their holdings of the stock. Creative Planning purchased a new position in shares of Inventiva in the 2nd quarter worth about $32,000. Wealth Enhancement Advisory Services LLC increased its stake in Inventiva by 54.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock valued at $50,000 after purchasing an additional 5,843 shares in the last quarter. NewEdge Advisors LLC purchased a new position in Inventiva in the third quarter worth about $116,000. Finally, Millennium Management LLC purchased a new stake in shares of Inventiva during the third quarter valued at approximately $649,000. 19.06% of the stock is currently owned by institutional investors.

Inventiva Trading Up 3.8%

The stock’s fifty day moving average price is $4.35 and its 200 day moving average price is $4.50.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.